NL-OMON48618
Completed
Not Applicable
Early clinical and biomarker responses after treatment in patients with non-segmental vitiligo - Early responses in vitiligo
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Vitiligo
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 36
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Patients with non\-segmental vitiligo commencing standard of care treatment,
- •consisting of a potent topical corticosteroid, such as FP cream, alone or in
- •combination with NB\-UVB phototherapy for at least 6 months.
- •\- Patients with new lesions and/or signs of disease progression (active
- •disease) within the past 6 months prior to Screening.
- •\- Males and females aged \*18
- •\- Patients able to communicate well with the investigator, to understand the
- •requirements of the study, as well as understand and sign the written informed
Exclusion Criteria
- •\- Patients that have received phototherapy or systemic immunosuppressive
- •treatment during the last 6 weeks prior to Screening.
- •\- Patients that have received topical anti\-inflammatory treatment (topical
- •corticosteroids, calcineurin inhibitors) during the last 4 weeks prior to
- •\- Patients currently receiving treatments other than potent topical
- •corticosteroids, such as FP 0\.05% cream, calcineurin inhibitors (tacrolimus,
- •pimecrolimus) or NB\-UVB phototherapy for non\-segmental vitiligo.
- •\- Recurrent HSV skin infections.
- •\- Patients with a history of hypertrophic scars or keloid.
- •\- Patients with a history of hypersensitivity to (UVB or UVA) light and/or
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Biomarkers Impact On the response to Treatment with Erlotinibon-small cell lung cancerEUCTR2009-017063-42-RORoche Romania SR
Not yet recruiting
Phase 4
Comparing efficacy of oral immunosuppressants in patients with moderate to severe psoriasisHealth Condition 1: L409- Psoriasis, unspecifiedCTRI/2024/05/068034Surbhi Jain Self
Completed
Phase 4
Evaluation of Clinical Outcomes Following Treatment with Systane® Balance in Dry Eye Subjects with Lipid DeficiencyNL-OMON38494Alcon Laboratories48
Completed
Not Applicable
Clinical Investigation of Patient Outcomes after IOL Implantation with Different IOL Delivery SystemsH26.9Cataract, unspecifiedDRKS00020134Alcon Research, LLC24
Not yet recruiting
Phase 2
Assessment of before and after outcome of bacterial vaginosis by homoeopathic medicine in reproductive age group women comparing its effect through in- vitroCTRI/2024/05/066638ational Institute of Homoeopathy